Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells

Adams, 2007, Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa, Planta Med., 73, 1554, 10.1055/s-2007-993743 Bergman, 1985, Studies of rutaecarpine and related quinazolinocarboline alkaloids, J. Org. Chem., 50, 1246, 10.1021/jo00208a018 Champoux, 2001, DNA topoisomerases: structure, function, and mechanism, Annu. Rev. Biochem., 70, 369, 10.1146/annurev.biochem.70.1.369 Chan, 2009, Evodiamine stabilizes topoisomerase I–DNA cleavable complex to inhibit topoisomerase I activity, Molecules, 14, 1342, 10.3390/molecules14041342 Chen, 1994, DNA topoisomerases—essential enzymes and lethal targets, Annu. Rev. Pharmacol. Toxicol., 34, 191, 10.1146/annurev.pa.34.040194.001203 Chen, 2010, Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO, J. Cell. Biochem., 110, 1495, 10.1002/jcb.22716 Hajji, 2005, Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor, Mutat. Res., 583, 26, 10.1016/j.mrgentox.2005.01.012 Huang, 2005, Induction of mitotic arrest and apoptosis in human prostate cancer PC-3 cells by evodiamine, J. Urol., 173, 256, 10.1097/01.ju.0000141587.72429.e3 Huang, 2004, Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes, Life Sci., 75, 35, 10.1016/j.lfs.2003.11.025 Kanzawa, 1990, Establishment of a camptothecin analog (Cpt-11)-resistant cell-line of human non-small cell lung-cancer—characterization and mechanism of resistance, Cancer Res., 50, 5919 Kapoor, 1995, Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin, Oncol. Res., 7, 83 Larsen, 2003, Catalytic topoisomerase II inhibitors in cancer therapy, Pharmacol. Ther., 99, 167, 10.1016/S0163-7258(03)00058-5 Liu, 1989, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem., 58, 351, 10.1146/annurev.bi.58.070189.002031 Liu, 2005, Preparative isolation and purification of alkaloids from the Chinese medicinal herb Evodia rutaecarpa (Juss.) Benth by high-speed counter-current chromatography, J. Chromatogr. A, 1074, 139, 10.1016/j.chroma.2005.03.099 Long, 2000, Non-camptothecin topoisomerase I active compounds as potential anticancer agents, Expert. Opin. Ther. Pat., 10, 635, 10.1517/13543776.10.5.635 Lu, 2009, Rapid and preparative separation of traditional Chinese medicine Evodia rutaecarpa employing elution–extrusion and back-extrusion counter-current chromatography: comparative study, J. Chromatogr. A, 1216, 4140, 10.1016/j.chroma.2008.10.095 Mauro, 2002, Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients, Haematologica, 87, 926 Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival—application to proliferation and cyto-toxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 Ogasawara, 2002, Anti-invasive and metastatic activities of evodiamine, Biol. Pharm. Bull., 25, 1491, 10.1248/bpb.25.1491 Peixoto, 2010, Topoisomerase I-mediated DNA relaxation as a tool to study intercalation of small molecules into supercoiled DNA Pommier, 2009, The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives, Mol. Cancer Ther., 8, 1008, 10.1158/1535-7163.MCT-08-0706 Pommier, 1985, Effects of the DNA intercalators 4′-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage, Biochemistry, 24, 6410, 10.1021/bi00344a015 Pommier, 1998, Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme, Biochim. Biophys. Acta: Gene Struct. Expression, 1400, 83, 10.1016/S0167-4781(98)00129-8 Pommier, 1985, Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei, Biochemistry, 24, 6406, 10.1021/bi00344a014 Riemsma, 2010, Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer, BMC Cancer, 10, 436, 10.1186/1471-2407-10-436 Riou, 1993, Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities, Cancer Res., 53, 5987 Spanswick, 2010, Measurement of DNA interstrand crosslinking in individual cells using the single cell gel electrophoresis (comet) assay Sugimoto, 1990, Decreased expression of DNA topoisomerase-I in camptothecin-resistant tumor-cell lines as determined by a monoclonal-antibody, Cancer Res., 50, 6925 Teicher, 2008, Next generation topoisomerase I inhibitors: rationale and biomarker strategies, Biochem. Pharmacol., 75, 1262, 10.1016/j.bcp.2007.10.016 Wang, 1994, DNA topoisomerases as targets of therapeutics: an overview, Adv. Pharmacol., 29A, 1, 10.1016/S1054-3589(08)60537-2 Wang, 1996, DNA topoisomerases, Annu. Rev. Biochem., 65, 635, 10.1146/annurev.bi.65.070196.003223 Wang, 2002, Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell Biol., 3, 430, 10.1038/nrm831 Willmore, 2011, Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia, Br. J. Haematol., 152, 61, 10.1111/j.1365-2141.2010.08425.x Wiseman, 1996, Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer, Drugs, 52, 606, 10.2165/00003495-199652040-00013 Woynarowski, 1989, Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin. Hoechst 33258, and 4′,6-diamidine-2-phenylindole, Mol. Pharmacol., 35, 177 Zhang, 2003, Intracellular regulation of evodiamine-induced A375-S2 cell death, Biol. Pharm. Bull., 26, 1543, 10.1248/bpb.26.1543 Zhang, 2004, Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa, J. Asian Nat. Prod. Res., 6, 19, 10.1080/1028602031000119772